• 1. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990
• 2. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 3. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966
• 4. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847
• 5. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651

Introduction to 1H-Benzimidazole-2-methanamine,5,6-dichloro (CAS No. 29096-76-2)

The compound 1H-Benzimidazole-2-methanamine,5,6-dichloro (CAS No. 29096-76-2) is a significant molecule in the field of pharmaceutical chemistry and bioorganic synthesis. Its unique structural framework, featuring a benzimidazole core substituted with chloro and aminomethyl groups, positions it as a versatile intermediate in the development of various bioactive agents. This introduction delves into the chemical properties, synthetic pathways, and emerging applications of this compound, emphasizing its relevance in contemporary medicinal chemistry research.

The benzimidazole scaffold is a privileged structure in drug discovery due to its broad spectrum of biological activities. Compounds derived from benzimidazole have been extensively explored for their roles as antiviral, anticancer, antimicrobial, and anti-inflammatory agents. The introduction of chlorine atoms at the 5 and 6 positions of the benzimidazole ring enhances the electron-withdrawing effect, which can modulate the reactivity and binding affinity of the molecule. Additionally, the presence of a 2-aminoethyl side chain provides a site for further functionalization, enabling the construction of more complex pharmacophores.

The synthesis of 1H-Benzimidazole-2-methanamine,5,6-dichloro typically involves multi-step organic transformations starting from commercially available precursors. One common approach involves the condensation of o-phenylenediamine derivatives with glyoxal or its equivalents to form the benzimidazole core. Subsequent chlorination using reagents such as phosphorus oxychloride (POCl?) or sulfuryl chloride (SO?Cl?) introduces the dichloro substituents at the 5 and 6 positions. The final step often includes nucleophilic substitution or reduction to introduce the aminomethyl group at the 2-position.

Recent advancements in synthetic methodologies have improved the efficiency and scalability of producing 1H-Benzimidazole-2-methanamine,5,6-dichloro. For instance, catalytic hydrogenation techniques have been employed to selectively reduce nitro or cyano groups into amines without affecting other functional moieties. Transition-metal-catalyzed cross-coupling reactions have also been utilized to introduce various substituents with high regioselectivity and yield. These innovations have not only streamlined the synthesis but also opened new avenues for structural diversification.

The biological significance of 1H-Benzimidazole-2-methanamine,5,6-dichloro has been highlighted in several cutting-edge research studies. In particular, its derivatives have shown promising activity against kinases and other enzymes implicated in cancer progression. Structural modifications based on this core scaffold have led to compounds that exhibit potent inhibitory effects on targets such as tyrosine kinases and cyclin-dependent kinases (CDKs). These findings underscore the importance of 1H-Benzimidazole-2-methanamine,5,6-dichloro as a key building block in oncology research.

Moreover, recent investigations have explored the antimicrobial properties of benzimidazole derivatives. The dichloro substitution pattern enhances the compound's ability to interact with bacterial enzymes and DNA gyrase, leading to inhibition of bacterial growth. This has prompted further studies into developing novel antibiotics based on modified benzimidazole structures. The aminomethyl group in 1H-Benzimidazole-2-methanamine,5,6-dichloro serves as a handle for appending additional pharmacophoric elements that could improve solubility and bioavailability.

In conclusion,1H-Benzimidazole-2-methanamine,5,6-dichloro (CAS No. 29096-76-2) is a multifaceted compound with significant potential in pharmaceutical applications. Its unique structural features make it an invaluable intermediate for synthesizing bioactive molecules targeting various diseases. As research continues to uncover new therapeutic opportunities derived from benzimidazole scaffolds,1H-Benzimidazole,5,6-dichloro will undoubtedly remain at the forefront of medicinal chemistry innovation.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)